Q-omics provides the consensus-scored RAB33A profile across patient tissues and cancer cell-line models. RAB33A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RAB33A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RAB33A protein abundance shows 33,729 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where RAB33A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB33A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB33A survival associations across molecular data types. RAB33A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB33A RNA expression–survival associations across cancer types. High RAB33A expression shows unfavorable associations in KIRP and UVM, but favorable associations in UCEC, KIRC, HNSC and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RAB33A RNA expression.
This table summarizes RAB33A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB33A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB33A shows lower tumor expression in COAD, UCEC and KICH and higher tumor expression in HNSC, KIRC and BRCA. The HNSC box plot shows higher RAB33A RNA expression in tumor versus normal tissue (log2 FC = +0.631, t-test p < 0.001).
This table shows molecular features associated with RAB33A in patient tissues and cancer cell lines. In patient samples, RAB33A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB33A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
